Shunji Endo1,2, Yukinori Kurokawa3, Makio Gamoh4, Yutaka Kimura5, Jin Matsuyama2, Hirokazu Taniguchi6, Atsushi Takeno7, Ryohei Kawabata8, Junji Kawada9, Toru Masuzawa10, Kazuyoshi Yamamoto11, Kouji Kobayashi12, Daisuke Sakai13, Toshio Shimokawa14, Taroh Satoh13. 1. Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Osaka, Japan. 2. Department of Surgery, Yao Municipal Hospital, Osaka, Japan. 3. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan ykurokawa@gesurg.med.osaka-u.ac.jp. 4. Department of Medical Oncology, Osaki Citizen Hospital, Miyagi, Japan. 5. Department of Gastroenterological Surgery, Sakai City Medical Center, Osaka, Japan. 6. Department of Surgery, Minoh City Hospital, Osaka, Japan. 7. Department of Gastroenterological Surgery, Kansai Rosai Hospital, Hyogo, Japan. 8. Department of Surgery, Osaka Rosai Hospital, Osaka, Japan. 9. Department of Surgery, Kaizuka City Hospital, Osaka, Japan. 10. Department of Surgery, Osaka Police Hospital, Osaka, Japan. 11. Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan. 12. Department of Internal Medicine, Showa University Northern Yokohama Hospital, Kanagawa, Japan. 13. Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan. 14. Clinical Study Support Center, Wakayama Medical University, Wakayama, Japan.
Abstract
BACKGROUND/AIM: Trastuzumab with S-1 plus cisplatin was proved to be effective for human epidermal growth factor receptor type 2 (HER2)-positive advanced gastric cancer with measurable lesions. However, the efficacy and safety of this regimen in the absence of measurable lesions are unknown. PATIENTS AND METHODS: Patients with HER2-positive gastric cancer without measurable lesions received cisplatin plus trastuzumab intravenously on day 1 and oral S-1 on days 1-14 of a 21-day cycle. The primary end-point was overall survival, and 40 patients were planned to be enrolled. RESULTS: Fifteen patients were enrolled. The median overall survival was 14.4 months. The 1- and 3-year overall survival rates were 66.7 % and 26.7 %, respectively. Major grade 3-4 adverse events included neutropenia (47%), anemia (40%), diarrhea (20%), nausea (20%), and anorexia (20%). CONCLUSION: Trastuzumab with S-1 plus cisplatin might be effective and tolerable for HER2-positive advanced gastric cancer without measurable lesions. Copyright
BACKGROUND/AIM: Trastuzumab with S-1 plus cisplatin was proved to be effective for human epidermal growth factor receptor type 2 (HER2)-positive advanced gastric cancer with measurable lesions. However, the efficacy and safety of this regimen in the absence of measurable lesions are unknown. PATIENTS AND METHODS: Patients with HER2-positive gastric cancer without measurable lesions received cisplatin plus trastuzumab intravenously on day 1 and oral S-1 on days 1-14 of a 21-day cycle. The primary end-point was overall survival, and 40 patients were planned to be enrolled. RESULTS: Fifteen patients were enrolled. The median overall survival was 14.4 months. The 1- and 3-year overall survival rates were 66.7 % and 26.7 %, respectively. Major grade 3-4 adverse events included neutropenia (47%), anemia (40%), diarrhea (20%), nausea (20%), and anorexia (20%). CONCLUSION:Trastuzumab with S-1 plus cisplatin might be effective and tolerable for HER2-positive advanced gastric cancer without measurable lesions. Copyright